PhInc. Modeling is a Contract Research Organization (CRO) specialized in quantitative pharmacology solutions to support biotechs in the development of drug candidates, new chemical entities, and biological entities. The company relies on the Model-Informed Drug Development (MIDD) approach to make informed decisions supported by analyses and modeling.

This strategy allows PhInc. Modeling to integrate quantitative modeling and simulations to optimize drug development, predict pharmacological responses, and identify the best dosing strategies.

By using mathematical models and simulations, PhInc. Modeling can anticipate the effects of a drug candidate in different populations and conditions, thereby reducing risks and costs associated with clinical development. Through MIDD, the company aims to improve the efficiency of clinical trials and accelerate the market entry of new treatments.

ALPX, an EMBL spin-off, provides comprehensive structural biology services to accelerate drug discovery programs. They specialize in delivering rapid and reliable structural insights for biotech and pharmaceutical partners, leveraging their expertise across X-ray crystallography, cryo-EM, and protein production.
Their core strength lies in their integrated, transparent, and flexible high-throughput protein-to-structure pipelines, designed to address challenging targets and timelines.

• X-ray Crystallography: ALPX offers end-to-end services from protein crystallization to structure determination, including compound and fragment screening. ALPX’s operations are supported by proprietary technologies like CrystalDirect™ and CRIMS and enabled by weekly access to synchrotron beamlines, ensuring swift delivery of high-quality data.

• Cryo-EM: ALPX provides a streamlined workflow from sample preparation and grid screening to data collection and high-resolution structure determination. Their process is supported by collaborations with leading imaging centers and robust cloud-based processing infrastructure, allowing them to manage complex projects efficiently.

• Protein Production: ALPX delivers optimized protein expression and purification services tailored for downstream structural studies. Their deep understanding of diverse protein targets ensures the production of high-quality material, which is a critical foundation for successful structural campaigns.

ALPX has extensive experience in solving structures for challenging targets and complex systems such as large protein complexes, molecular glues and PROTACs, protein-antibody and protein-DNA complexes and membrane proteins. Their automated platforms and deep scientific expertise enable them to deliver structural data with speed and precision, helping their partners advance their projects from early hits to validated lead candidates.

QIMA Life Sciences empowers global leaders in pharmaceutical, biotech, and cosmetic industries with science-driven, predictive preclinical and clinical models and evaluations. Their solutions accelerate development, enhance success rates, and optimize resources by identifying the most promising candidates or active ingredients early in the pipeline. With deep scientific expertise, they serve as a trusted partner—delivering robust data that strengthens decision-making and fuels innovation at every stage of product development—because better science leads to better lives.

Specialist in preclinical proof-of-concept and efficacy studies

Motac Neuroscience, with operations in Bordeaux (France) and Beijing (China), is a CRO specialized in preclinical research for neurological and neurodegenerative disorders. Motac Neuroscience supports biotechnology and pharmaceutical companies by generating robust and translationally relevant preclinical data to advance therapeutic candidates toward clinical development.

Motac Neuroscience provides integrated platforms combining rodent and non-human primate models with behavioral assessments, in vivo imaging, biomarker analysis and histopathological endpoints. These multidisciplinary approaches generate comprehensive datasets that support critical decision-making from proof-of-concept to IND-enabling studies.

Motac Neuroscience has expert experience in neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease and amyotrophic lateral sclerosis, as well as other neurological conditions including spinal cord injury, cognitive impairment and sleep–wake disorders. The company designs and conducts customized studies aimed at reducing development risk and supporting the translation of innovative therapies targeting central nervous system disorders.

SEQENS is a global leader in the pharmaceutical industry, with over 30 years’ experience in the development and manufacturing of APIs, intermediates and polymers.

Seqens’ state-of-the-art R&D facilities in Europe and in the US, along with its network of 8 manufacturing sites (GMP and non‑GMP), enable the company to innovate, develop and industrialize the most demanding molecules and implement the best available technologies.

Seqens supports its customers from early‑stage development to commercial production, offering tailored solutions for complex molecules.

As a trusted partner to over 1,000 customers worldwide, Seqens is backed by a strong CMC project management team, offering the highest level of service and commitment.

Antineo is a Contract Research Organization (CRO) founded in May 2015, specialized in preclinical proof-of-concept studies for anticancer agents.

Antineo’s activity is based on providing services for the evaluation of new anticancer compounds (small molecules, antibodies, peptides, etc.). The company offers scientific consulting and supports its clients in optimizing the development of their anticancer candidates through a range of services covering in vitro assays (cell toxicity, sample characterization), ex vivo analyses (mechanism of action or target identification by flow cytometry), and in vivo studies (antitumor efficacy, toxicity, pharmacokinetics).

The company maintains a collection of more than 150 human and murine tumor cell lines representing various cancer types (colon cancer, breast cancer, genetically mutated cancers, etc.). These cell lines are derived from patient tumors collected during surgery and subsequently cultured and stabilized as established cell lines. The advantage of these tumor cell lines is their high stability and reproducibility, both for in vitro experiments and for xenograft studies in mice. In this context, tumor cell lines are implanted into immunodeficient mice, which do not reject the xenograft, and different experimental groups are treated with the compounds of interest. The company also offers patient-derived xenograft models.

The evaluation of immunotherapeutic agents may also require complex preclinical models with an intact immune system. In syngeneic models, the team uses immortalized murine cancer cell lines that are allografted into immunocompetent mice of the same inbred strain. These models offer several advantages, including a fully functional immune system, making them suitable for evaluating the efficacy of new cancer immunotherapy approaches.

Antineo also conducts internal R&D activities, through which the company develops original models of resistance to standard-of-care therapies, particularly immune checkpoint inhibitors currently available on the market, in order to evaluate the efficacy of new anticancer treatments. In addition, Antineo develops in vitro 3D-printed tumor models.

Antineo is also actively involved at the European level through participation in joint research projects (EUROSTARS).